Want to learn more about the latest in using plasma exchange in ANCA-associated vasculitis? (if you’re a nephrologist, of course you do!)
Check out this rapid summary below!
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.
Want to learn more about the latest in using plasma exchange in ANCA-associated vasculitis? (if you’re a nephrologist, of course you do!)
Check out this rapid summary below!
✳️ #TenTweetNephJC ✳️
— Nephrology Jrnl Club (@NephJC) April 8, 2022
👉 where we catch you up on the week's #NephJC chat in 10 tweets
The topic at hand was Plasma Exchange and Vasculitis: the infamous debate of to PLEX or not to PLEX in AAV
Check out this thread to see if you change your mind on this comPLEX topic 👇 pic.twitter.com/PvW0C0O9R9